Lerdelimumab.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005128:Eye Diseases / Q000628:therapy; D006801:Humans; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000276:immunology*; D053781:Transforming Growth Factor beta2
D000911:Antibodies, Monoclonal; C509041:TGFB2 protein, human; D016212:Transforming Growth Factor beta; D053781:Transforming Growth Factor beta2